Moderna (MRNA) set to cure COVID-19 – is now the time to invest?

MRNA’s key COVID-19 developments so far

  • US government is willing to fund mRNA-173 through every trial until regulatory approval.
  • Biomedical Advanced Research and Development Authority (BARDA) is ready to give Moderna (NASDAQ: MRNA) $483 million to expedite mRNA-173 through clinical development.
  • Lonza Group, via its agreement with Moderna, is manufacturing mRNA-173 at their US and Switzerland operations.
Read more